| pubmed-article:19560557 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19560557 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:19560557 | lifeskim:mentions | umls-concept:C0745744 | lld:lifeskim |
| pubmed-article:19560557 | lifeskim:mentions | umls-concept:C0332161 | lld:lifeskim |
| pubmed-article:19560557 | lifeskim:mentions | umls-concept:C1301416 | lld:lifeskim |
| pubmed-article:19560557 | lifeskim:mentions | umls-concept:C0339897 | lld:lifeskim |
| pubmed-article:19560557 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:19560557 | lifeskim:mentions | umls-concept:C2698977 | lld:lifeskim |
| pubmed-article:19560557 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:19560557 | pubmed:dateCreated | 2009-11-5 | lld:pubmed |
| pubmed-article:19560557 | pubmed:abstractText | Cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites or recurrent variceal bleeding are at risk for decompensation and death. This study examined whether a new model for end stage liver disease (MELD), which incorporates serum sodium (MELDNa), is a better predictor of death or transplant after TIPS than the original MELD. | lld:pubmed |
| pubmed-article:19560557 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19560557 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19560557 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19560557 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19560557 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19560557 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19560557 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19560557 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19560557 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19560557 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19560557 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19560557 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19560557 | pubmed:issn | 1542-7714 | lld:pubmed |
| pubmed-article:19560557 | pubmed:author | pubmed-author:BigginsScott... | lld:pubmed |
| pubmed-article:19560557 | pubmed:author | pubmed-author:ShiboskiSteph... | lld:pubmed |
| pubmed-article:19560557 | pubmed:author | pubmed-author:InadomiJohn... | lld:pubmed |
| pubmed-article:19560557 | pubmed:author | pubmed-author:KerlanRobertR | lld:pubmed |
| pubmed-article:19560557 | pubmed:author | pubmed-author:SomsoukMaM | lld:pubmed |
| pubmed-article:19560557 | pubmed:author | pubmed-author:GuyJenniferJ | lld:pubmed |
| pubmed-article:19560557 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19560557 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:19560557 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19560557 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19560557 | pubmed:pagination | 1236-40 | lld:pubmed |
| pubmed-article:19560557 | pubmed:dateRevised | 2011-4-29 | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:meshHeading | pubmed-meshheading:19560557... | lld:pubmed |
| pubmed-article:19560557 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19560557 | pubmed:articleTitle | New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. | lld:pubmed |
| pubmed-article:19560557 | pubmed:affiliation | Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California, USA. jennifer.guy@ucsf.edu | lld:pubmed |
| pubmed-article:19560557 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19560557 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19560557 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19560557 | lld:pubmed |
